company background image
CTLT

Catalent NYSE:CTLT Stock Report

Last Price

US$79.79

Market Cap

US$13.8b

7D

9.7%

1Y

-38.7%

Updated

04 Oct, 2022

Data

Company Financials +
CTLT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance2/6
Financial Health3/6
Dividends0/6

CTLT Stock Overview

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide.

Catalent Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Catalent
Historical stock prices
Current Share PriceUS$79.79
52 Week HighUS$140.56
52 Week LowUS$72.19
Beta1.36
1 Month Change-8.90%
3 Month Change-26.93%
1 Year Change-38.71%
3 Year Change67.27%
5 Year Change89.03%
Change since IPO299.15%

Recent News & Updates

Sep 16
Calculating The Fair Value Of Catalent, Inc. (NYSE:CTLT)

Calculating The Fair Value Of Catalent, Inc. (NYSE:CTLT)

Does the September share price for Catalent, Inc. ( NYSE:CTLT ) reflect what it's really worth? Today, we will estimate...

Shareholder Returns

CTLTUS PharmaceuticalsUS Market
7D9.7%1.2%1.0%
1Y-38.7%4.4%-20.0%

Return vs Industry: CTLT underperformed the US Pharmaceuticals industry which returned 4.4% over the past year.

Return vs Market: CTLT underperformed the US Market which returned -20% over the past year.

Price Volatility

Is CTLT's price volatile compared to industry and market?
CTLT volatility
CTLT Average Weekly Movement6.1%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CTLT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: CTLT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200719,000Alessandro Masellihttps://www.catalent.com

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services.

Catalent Fundamentals Summary

How do Catalent's earnings and revenue compare to its market cap?
CTLT fundamental statistics
Market CapUS$13.77b
Earnings (TTM)US$503.00m
Revenue (TTM)US$4.83b

28.5x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTLT income statement (TTM)
RevenueUS$4.83b
Cost of RevenueUS$3.19b
Gross ProfitUS$1.64b
Other ExpensesUS$1.14b
EarningsUS$503.00m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.80
Gross Margin33.97%
Net Profit Margin10.42%
Debt/Equity Ratio82.8%

How did CTLT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CTLT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CTLT?

Other financial metrics that can be useful for relative valuation.

CTLT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.6x
Enterprise Value/EBITDA14.9x
PEG Ratio2.2x

Price to Earnings Ratio vs Peers

How does CTLT's PE Ratio compare to its peers?

CTLT PE Ratio vs Peers
The above table shows the PE ratio for CTLT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average30.4x
VTRS Viatris
13.9x18.0%US$10.6b
RPRX Royalty Pharma
37.7x54.5%US$24.4b
OGN Organon
5.5x4.8%US$6.1b
PCRX Pacira BioSciences
64.3x15.8%US$2.5b
CTLT Catalent
28.5x13.0%US$13.8b

Price-To-Earnings vs Peers: CTLT is good value based on its Price-To-Earnings Ratio (28.5x) compared to the peer average (30.4x).


Price to Earnings Ratio vs Industry

How does CTLT's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Earnings vs Industry: CTLT is expensive based on its Price-To-Earnings Ratio (28.5x) compared to the US Pharmaceuticals industry average (12.7x)


Price to Earnings Ratio vs Fair Ratio

What is CTLT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CTLT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.5x
Fair PE Ratio25.6x

Price-To-Earnings vs Fair Ratio: CTLT is expensive based on its Price-To-Earnings Ratio (28.5x) compared to the estimated Fair Price-To-Earnings Ratio (25.6x).


Share Price vs Fair Value

What is the Fair Price of CTLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CTLT ($79.79) is trading below our estimate of fair value ($102.43)

Significantly Below Fair Value: CTLT is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Catalent forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


13.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTLT's forecast earnings growth (13% per year) is above the savings rate (1.9%).

Earnings vs Market: CTLT's earnings (13% per year) are forecast to grow slower than the US market (14.7% per year).

High Growth Earnings: CTLT's earnings are forecast to grow, but not significantly.

Revenue vs Market: CTLT's revenue (8.1% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: CTLT's revenue (8.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CTLT's Return on Equity is forecast to be low in 3 years time (13.8%).


Discover growth companies

Past Performance

How has Catalent performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


43.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CTLT has high quality earnings.

Growing Profit Margin: CTLT's current net profit margins (10.4%) are lower than last year (13.2%).


Past Earnings Growth Analysis

Earnings Trend: CTLT's earnings have grown significantly by 43.5% per year over the past 5 years.

Accelerating Growth: CTLT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CTLT had negative earnings growth (-4.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (5%).


Return on Equity

High ROE: CTLT's Return on Equity (10.8%) is considered low.


Discover strong past performing companies

Financial Health

How is Catalent's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CTLT's short term assets ($2.9B) exceed its short term liabilities ($1.1B).

Long Term Liabilities: CTLT's short term assets ($2.9B) do not cover its long term liabilities ($4.6B).


Debt to Equity History and Analysis

Debt Level: CTLT's net debt to equity ratio (71.5%) is considered high.

Reducing Debt: CTLT's debt to equity ratio has reduced from 286.1% to 82.8% over the past 5 years.

Debt Coverage: CTLT's debt is not well covered by operating cash flow (11.1%).

Interest Coverage: CTLT's interest payments on its debt are well covered by EBIT (6.5x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Catalent current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Catalent Dividend Yield vs Market
How does Catalent dividend yield compare to the market?
SegmentDividend Yield
Company (Catalent)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Catalent)0%

Notable Dividend: Unable to evaluate CTLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CTLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTLT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTLT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CTLT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Alessandro Maselli (50 yo)

0.25yr

Tenure

US$3,234,030

Compensation

Mr. Alessandro Maselli has been President and Chief Operation Officer of Catalent Pharma Solutions, Inc. from February 2019 and serves as its Director since July 01, 2022. He served as Senior Vice Presiden...


CEO Compensation Analysis

Alessandro Maselli's Compensation vs Catalent Earnings
How has Alessandro Maselli's remuneration changed compared to Catalent's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022US$3mUS$654k

US$503m

Mar 31 2022n/an/a

US$485m

Dec 31 2021n/an/a

US$561m

Sep 30 2021n/an/a

US$544m

Jun 30 2021US$5mUS$640k

US$529m

Mar 31 2021n/an/a

US$494m

Dec 31 2020n/an/a

US$289m

Sep 30 2020n/an/a

US$250m

Jun 30 2020US$3mUS$483k

US$173m

Mar 31 2020n/an/a

US$104m

Dec 31 2019n/an/a

US$124m

Sep 30 2019n/an/a

US$138m

Jun 30 2019US$2mUS$450k

US$132m

Compensation vs Market: Alessandro's total compensation ($USD3.23M) is below average for companies of similar size in the US market ($USD13.04M).

Compensation vs Earnings: Alessandro's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CTLT's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: CTLT's board of directors are considered experienced (7.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CTLT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

NYSE:CTLT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Aug 22SellUS$39,567Jonathan ArnoldIndividual384US$103.04
25 Aug 22SellUS$189,594Scott GuntherIndividual1,840US$103.04
25 Aug 22SellUS$156,312Ricky HopsonIndividual1,517US$103.04
25 Aug 22SellUS$152,705Michael RileyIndividual1,482US$103.04
25 Aug 22SellUS$106,440Lorenzo CarlettiIndividual1,033US$103.04
25 Aug 22SellUS$169,501Aristippos GennadiosIndividual1,645US$103.04
25 Aug 22SellUS$478,724Alessandro MaselliIndividual4,646US$103.04
25 Aug 22SellUS$180,011Ricardo PravdaIndividual1,747US$103.04
25 Aug 22SellUS$145,699Thomas CastellanoIndividual1,414US$103.04
25 Aug 22SellUS$136,116Kay SchmidtIndividual1,321US$103.04
25 Aug 22SellUS$4,011,759John ChiminskiIndividual38,934US$103.04
25 Aug 22SellUS$495,725Steven FasmanIndividual4,811US$103.04
25 Aug 22SellUS$163,421Mario GargiuloIndividual1,586US$103.04
25 Aug 22SellUS$172,077Michael GrippoIndividual1,670US$103.04
25 Aug 22SellUS$34,931Trish HuntIndividual339US$103.04
25 Aug 22SellUS$339,620Manja BoermanIndividual3,296US$103.04
25 Aug 22SellUS$69,140Tom HawkeswoodIndividual671US$103.04
26 Jul 22SellUS$10,049Jonathan ArnoldIndividual94US$106.90
26 Jul 22SellUS$67,454Lorenzo CarlettiIndividual631US$106.90
26 Jul 22SellUS$37,094Thomas CastellanoIndividual347US$106.90
26 Jul 22SellUS$1,035,968John ChiminskiIndividual9,691US$106.90
26 Jul 22SellUS$272,167Steven FasmanIndividual2,546US$106.90
26 Jul 22SellUS$103,586Mario GargiuloIndividual969US$106.90
26 Jul 22SellUS$43,722Michael GrippoIndividual409US$106.90
26 Jul 22SellUS$45,646Ricardo PravdaIndividual427US$106.90
26 Jul 22SellUS$43,081Aristippos GennadiosIndividual403US$106.90
26 Jul 22SellUS$48,105Scott GuntherIndividual450US$106.90
26 Jul 22SellUS$33,353Ricky HopsonIndividual312US$106.90
26 Jul 22SellUS$87,230Alessandro MaselliIndividual816US$106.90
26 Jul 22SellUS$34,529Kay SchmidtIndividual323US$106.90
10 Jun 22SellUS$12,578Mario GargiuloIndividual118US$106.59
06 Feb 22SellUS$49,999,994Leonard Green & Partners, L.P.Company487,092US$102.65
23 Nov 21SellUS$645,407Gregory LucierIndividual5,068US$127.76

Ownership Breakdown

What is the ownership structure of CTLT?
Owner TypeNumber of SharesOwnership Percentage
State or Government74,5400.04%
Individual Insiders693,6030.4%
General Public13,864,6367.7%
Institutions165,263,15291.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.


Top Shareholders

Top 25 shareholders own 63.56% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.59%
The Vanguard Group, Inc.
19,044,799$1.5b0.39%0.03%
8.5%
BlackRock, Inc.
15,293,546$1.2b-2.16%0.03%
5.76%
Capital Research and Management Company
10,365,836$827.1m18.04%0.05%
3.92%
State Street Global Advisors, Inc.
7,059,746$563.3m-0.94%0.03%
3.9%
Janus Henderson Group plc
7,023,798$560.4m-6.62%0.29%
3.83%
Veritas Asset Management LLP
6,892,041$549.9m-1.54%2%
3.15%
Franklin Resources, Inc.
5,672,698$452.6m-2.51%0.18%
2.91%
Artisan Partners Limited Partnership
5,232,772$417.5m20.43%0.39%
2.41%
Leonard Green & Partners, L.P.
4,330,462$345.5m0%5.15%
2.32%
J.P. Morgan Asset Management, Inc.
4,175,643$333.2m0.72%0.06%
1.98%
American Century Investment Management Inc
3,568,591$284.7m83.56%0.2%
1.91%
Geode Capital Management, LLC
3,427,085$273.4m0.63%0.03%
1.22%
EARNEST Partners, LLC
2,193,042$175.0m13.84%1.07%
1.2%
T. Rowe Price Group, Inc.
2,162,950$172.6m-90.3%0.02%
1.12%
Invesco Ltd.
2,016,337$160.9m-20.58%0.05%
1.09%
Viking Global Investors LP
1,961,249$156.5m3.57%0.67%
1.01%
Northern Trust Global Investments
1,819,213$145.2m7.51%0.03%
0.97%
Allianz Asset Management AG
1,741,182$138.9m-8.1%0.11%
0.94%
Bessemer Investment Management LLC
1,685,065$134.5m25.37%0.27%
0.91%
Novo Holdings A/S
1,632,878$130.3m28.4%0.16%
0.83%
Norges Bank Investment Management
1,492,344$119.1m0%0.02%
0.81%
Columbia Management Investment Advisers, LLC
1,457,367$116.3m15.6%0.03%
0.78%
BNY Mellon Asset Management
1,406,616$112.2m1.6%0.02%
0.77%
Champlain Investment Partners, LLC
1,383,795$110.4m-1.11%0.67%
0.72%
TimesSquare Capital Management, LLC
1,293,950$103.2m0.06%1.17%

Company Information

Catalent, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Catalent, Inc.
  • Ticker: CTLT
  • Exchange: NYSE
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$13.766b
  • Shares outstanding: 179.90m
  • Website: https://www.catalent.com

Number of Employees


Location

  • Catalent, Inc.
  • 14 Schoolhouse Road
  • Somerset
  • New Jersey
  • 8873
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTLTNYSE (New York Stock Exchange)YesCommon StockUSUSDJul 2014
0C8DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2014
CTLT *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJul 2014

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Earnings2022/06/30
Annual Earnings2022/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.